Alnylam Pharmaceuticals, Inc. (0HD2.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 52.7B |
| Enterprise Value | 54.23B |
| P/E Ratio | 7.44 |
| PEG Ratio | 0 |
| Price/Sales Ratio | 4.05 |
| Price/Book Ratio | 5.63 |
| Enterprise/Revenue | 3.95 |
| Enterprise/EBITDA | 15.88 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | September 30, 2026 |
Profitability
| Profit Margin | 0.54 |
| Operating Margin | 0.2 |
AD
Management Effectiveness
| Return On Assets | 0.34 |
| Return On Equity | 1.6 |
Income Statement
| Revenue | 3.71B |
| Revenue/Share | 37.46 |
| Gross Profit | 3.03B |
| EBITDA | 557.24M |
| Net Income | 313.75M |
| Diluted EPS | 2.33 |
Balance Sheet
| Total Cash | 3.59B |
| Total Cash/Share | 26.8 |
| Total Debt | 3B |
| Total Debt/Equity | 0.35 |
| Current Ratio | 2.48 |
| Book Value Per Share | 26.93 |
Price History
| 52-Week Change | -66.03 |
| 52-Week High | 477.82 |
| 52-Week Low | 149.3 |
| Moving Average 50 Days | 225.41 |
| Moving Average 200 Days | 278.66 |
Statistics
| Average Volume | 654 |
| Shares Outstanding | 133.94M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
